The Japanese society is undergoing an accelerating process of aging，which increases the need for drugs and the pressure of higher medical expenditures.Japanese policies preventing the medical expenditures from increasing too rapidly have great impact on pharmaceutical enterprises.How to reach a balance between protecting enterprises' benefits regarding reference listed drugs and controlling drug prices in order to lower the medical expenditures？ The policy adjustment in Japan may be used for reference.